Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
immunomodulatory drug thalidomide analog |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AX06
|
| gptkbp:brand |
gptkb:Pomalyst
|
| gptkbp:CASNumber |
19171-19-8
|
| gptkbp:chemicalFormula |
C13H11N3O4
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
gptkb:Celgene
|
| gptkbp:eliminationHalfLife |
7.5 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
pomalidomide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
modulates immune system
inhibits angiogenesis |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
X
|
| gptkbp:relatedTo |
gptkb:thalidomide
gptkb:lenalidomide |
| gptkbp:sideEffect |
gptkb:anemia
fatigue infections neutropenia thrombocytopenia |
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:Darzalex
|
| gptkbp:bfsLayer |
6
|